Search

Your search keyword '"Pistelli, Mirco"' showing total 199 results
Start Over Author "Pistelli, Mirco"
199 results on '"Pistelli, Mirco"'

1. Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments

Author

Valenza, Carmine, Trapani, Dario, Gandini, Sara, Sposetti, Caterina, Boscolo Bielo, Luca, Marra, Antonio, Giarratano, Tommaso, Favero, Diletta, Cortesi, Laura, Moscetti, Luca, Pistelli, Mirco, Berardi, Rossana, Zambelli, Alberto, Lambertini, Matteo, Del Mastro, Lucia, Guarneri, Valentina, Vernieri, Claudio, and Curigliano, Giuseppe

Published
2023
Full Text
View/download PDF

2. A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients

Author

Coltelli, Luigi, Allegrini, Giacomo, Orlandi, Paola, Finale, Chiara, Fontana, Andrea, Masini, Luna Chiara, Scalese, Marco, Arrighi, Giada, Barletta, Maria Teresa, De Maio, Ermelinda, Banchi, Marta, Fini, Elisabetta, Guidi, Patrizia, Frenzilli, Giada, Donati, Sara, Giovannelli, Simona, Tanganelli, Lucia, Salvadori, Barbara, Livi, Lorenzo, Meattini, Icro, Pazzagli, Ilaria, Di Lieto, Marco, Pistelli, Mirco, Casadei, Virginia, Ferro, Antonella, Cupini, Samanta, Orlandi, Francesca, Francesca, Damiana, Lorenzini, Giulia, Barellini, Leonardo, Falcone, Alfredo, Cosimi, Alessandro, and Bocci, Guido

Published
2022
Full Text
View/download PDF

6. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

Author

Pizzuti, Laura, Barba, Maddalena, Mazzotta, Marco, Krasniqi, Eriseld, Maugeri-Saccà, Marcello, Gamucci, Teresa, Berardi, Rossana, Livi, Lorenzo, Ficorella, Corrado, Natoli, Clara, Cortesi, Enrico, Generali, Daniele, La Verde, Nicla, Cassano, Alessandra, Bria, Emilio, Moscetti, Luca, Michelotti, Andrea, Adamo, Vincenzo, Zamagni, Claudio, Tonini, Giuseppe, Sergi, Domenico, Marinelli, Daniele, Paoletti, Giancarlo, Tomao, Silverio, Botticelli, Andrea, Marchetti, Paolo, Tinari, Nicola, Grassadonia, Antonino, Valerio, Maria Rosaria, Mirabelli, Rosanna, Fabbri, Maria Agnese, D’Ostilio, Nicola, Veltri, Enzo, Corsi, Domenico, Garrone, Ornella, Paris, Ida, Sarobba, Giuseppina, Meattini, Icro, Pistelli, Mirco, Giotta, Francesco, Lorusso, Vito, Garufi, Carlo, Russo, Antonio, Cazzaniga, Marina, Del Medico, Pietro, Roselli, Mario, Vaccaro, Angela, Perracchio, Letizia, di Benedetto, Anna, Daralioti, Theodora, Sperduti, Isabella, De Maria, Ruggero, Di Leo, Angelo, Sanguineti, Giuseppe, Ciliberto, Gennaro, and Vici, Patrizia

Published
2021
Full Text
View/download PDF

10. Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

Author

Di Lisa, Francesca Sofia, primary, Krasniqi, Eriseld, additional, Pizzuti, Laura, additional, Barba, Maddalena, additional, Cannita, Katia, additional, De Giorgi, Ugo, additional, Borella, Fulvio, additional, Foglietta, Jennifer, additional, Cariello, Anna, additional, Ferro, Antonella, additional, Picardo, Elisa, additional, Mitidieri, Marco, additional, Sini, Valentina, additional, Stani, Simonetta, additional, Tonini, Giuseppe, additional, Santini, Daniele, additional, La Verde, Nicla, additional, Gambaro, Anna Rita, additional, Grassadonia, Antonino, additional, Tinari, Nicola, additional, Garrone, Ornella, additional, Sarobba, Giuseppina, additional, Livi, Lorenzo, additional, Meattini, Icro, additional, D’Auria, Giuliana, additional, Vergati, Matteo, additional, Gamucci, Teresa, additional, Pistelli, Mirco, additional, Berardi, Rossana, additional, Risi, Emanuela, additional, Giotta, Francesco, additional, Lorusso, Vito, additional, Rinaldi, Lucia, additional, Artale, Salvatore, additional, Cazzaniga, Marina Elena, additional, Zustovich, Fable, additional, Cappuzzo, Federico, additional, Landi, Lorenza, additional, Torrisi, Rosalba, additional, Scagnoli, Simone, additional, Botticelli, Andrea, additional, Michelotti, Andrea, additional, Fratini, Beatrice, additional, Saltarelli, Rosa, additional, Paris, Ida, additional, Muratore, Margherita, additional, Cassano, Alessandra, additional, Gianni, Lorenzo, additional, Gaspari, Valeria, additional, Veltri, Enzo Maria, additional, Zoratto, Federica, additional, Fiorio, Elena, additional, Fabbri, Maria Agnese, additional, Mazzotta, Marco, additional, Ruggeri, Enzo Maria, additional, Pedersini, Rebecca, additional, Valerio, Maria Rosaria, additional, Filomeno, Lorena, additional, Minelli, Mauro, additional, Scavina, Paola, additional, Raffaele, Mimma, additional, Astone, Antonio, additional, De Vita, Roy, additional, Pozzi, Marcello, additional, Riccardi, Ferdinando, additional, Greco, Filippo, additional, Moscetti, Luca, additional, Giordano, Monica, additional, Maugeri-Saccà, Marcello, additional, Zennaro, Alessandro, additional, Botti, Claudio, additional, Pelle, Fabio, additional, Cappelli, Sonia, additional, Cavicchi, Flavia, additional, Vizza, Enrico, additional, Sanguineti, Giuseppe, additional, Tomao, Federica, additional, Cortesi, Enrico, additional, Marchetti, Paolo, additional, Tomao, Silverio, additional, Speranza, Iolanda, additional, Sperduti, Isabella, additional, Ciliberto, Gennaro, additional, and Vici, Patrizia, additional

Published
2023
Full Text
View/download PDF

11. EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer

Author

Biganzoli, Laura, Cinieri, Saverio, Berardi, Rossana, Pedersini, Rebecca, McCartney, Amelia, Minisini, Alessandro Marco, Caremoli, Elena Rota, Spazzapan, Simon, Magnolfi, Emanuela, Brunello, Antonella, Risi, Emanuela, Palumbo, Raffaella, Leo, Silvana, Colleoni, Marco, Donati, Sara, De Placido, Sabino, Orlando, Laura, Pistelli, Mirco, Parolin, Veronica, Mislang, Anna, Becheri, Dimitri, Puglisi, Fabio, Sanna, Giuseppina, Zafarana, Elena, Boni, Luca, and Mottino, Giuseppe

Published
2020
Full Text
View/download PDF

16. Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review

Author

De Lisa, Mariagrazia, Ballatore, Zelmira, Marcantognini, Giulia, Pierantoni, Chiara, Antognoli, Stefania, Pistelli, Mirco, Pagliacci, Alessandra, and Berardi, Rossana

Abstract

Irinotecan-based regimens are used worldwide for the treatment of several recurrent or advanced gastrointestinal malignancies. In this paper we describe the cases of four patients treated in our institution who developed acute dysarthria while receiving intravenous infusion of irinotecan. In all our cases, dysarthria occurred during the infusion of the first course of irinotecan, and then resolved rapidly without any sequelae. Imaging of the brain was performed, but failed to show any evidence of an acute neurological event. We also reviewed the literature on this very uncommon adverse event. The pathogenesis of irinotecan-induced dysarthria is still unknown and is not completely elucidated by the current pharmacodynamic or kinetic explanations; therefore, we could only hypothesize some assumptions.

Published
2024
Full Text
View/download PDF

22. The Impact of Lifestyle Interventions in High-Risk Early Breast Cancer Patients: A Modeling Approach from a Single Institution Experience

Author

Pistelli, Mirco, primary, Natalucci, Valentina, additional, Scortichini, Laura, additional, Agostinelli, Veronica, additional, Lenci, Edoardo, additional, Crocetti, Sonia, additional, Merloni, Filippo, additional, Bastianelli, Lucia, additional, Taus, Marina, additional, Fumelli, Daniele, additional, Giulietti, Gloria, additional, Cola, Claudia, additional, Capecci, Marianna, additional, Serrani, Roberta, additional, Ceravolo, Maria Gabriella, additional, Ricci, Maurizio, additional, Nicolai, Albano, additional, Barbieri, Elena, additional, Nicolai, Giulia, additional, Ballatore, Zelmira, additional, Savini, Agnese, additional, and Berardi, Rossana, additional

Published
2021
Full Text
View/download PDF

23. Role of maspin in cancer

Author

Berardi, Rossana, Morgese, Francesca, Onofri, Azzurra, Mazzanti, Paola, Pistelli, Mirco, Ballatore, Zelmira, Savini, Agnese, De Lisa, Mariagrazia, Caramanti, Miriam, Rinaldi, Silvia, Pagliaretta, Silvia, Santoni, Matteo, Pierantoni, Chiara, and Cascinu, Stefano

Published
2013
Full Text
View/download PDF

25. sj-docx-1-tam-10.1177_17588359211059873 ��� Supplemental material for PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting

Author

Pizzuti, Laura, Krasniqi, Eriseld, Sperduti, Isabella, Barba, Maddalena, Gamucci, Teresa, Mauri, Maria, Veltri, Enzo Maria, Meattini, Icro, Berardi, Rossana, Di Lisa, Francesca Sofia, Natoli, Clara, Pistelli, Mirco, Iezzi, Laura, Risi, Emanuela, D���Ostilio, Nicola, Tomao, Silverio, Ficorella, Corrado, Cannita, Katia, Riccardi, Ferdinando, Cassano, Alessandra, Bria, Emilio, Fabbri, Maria Agnese, Mazzotta, Marco, Barchiesi, Giacomo, Botticelli, Andrea, D���Auria, Giuliana, Ceribelli, Anna, Michelotti, Andrea, Russo, Antonio, Salimbeni, Beatrice Taurelli, Sarobba, Giuseppina, Giotta, Francesco, Paris, Ida, Saltarelli, Rosa, Marinelli, Daniele, Corsi, Domenico, Capomolla, Elisabetta Maria, Sini, Valentina, Moscetti, Luca, Mentuccia, Lucia, Tonini, Giuseppe, Raffaele, Mimma, Marchetti, Luca, Minelli, Mauro, Ruggeri, Enzo Maria, Scavina, Paola, Bacciu, Olivia, Salesi, Nello, Livi, Lorenzo, Tinari, Nicola, Grassadonia, Antonino, Fedele Scinto, Angelo, Rossi, Rosalinda, Valerio, Maria Rosaria, Landucci, Elisabetta, Stani, Simonetta, Fratini, Beatrice, Maugeri-Sacc��, Marcello, De Tursi, Michele, Maione, Angela, Santini, Daniele, Orlandi, Armando, Lorusso, Vito, Cortesi, Enrico, Sanguineti, Giuseppe, Pinnar��, Paola, Cappuzzo, Federico, Landi, Lorenza, Botti, Claudio, Tomao, Federica, Cappelli, Sonia, Bon, Giulia, Pelle, Fabio, Cavicchi, Flavia, Fiorio, Elena, Foglietta, Jennifer, Scagnoli, Simone, Marchetti, Paolo, Ciliberto, Gennaro, and Vici, Patrizia

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tam-10.1177_17588359211059873 for PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting by Laura Pizzuti, Eriseld Krasniqi, Isabella Sperduti, Maddalena Barba, Teresa Gamucci, Maria Mauri, Enzo Maria Veltri, Icro Meattini, Rossana Berardi, Francesca Sofia Di Lisa, Clara Natoli, Mirco Pistelli, Laura Iezzi, Emanuela Risi, Nicola D���Ostilio, Silverio Tomao, Corrado Ficorella, Katia Cannita, Ferdinando Riccardi, Alessandra Cassano, Emilio Bria, Maria Agnese Fabbri, Marco Mazzotta, Giacomo Barchiesi, Andrea Botticelli, Giuliana D���Auria, Anna Ceribelli, Andrea Michelotti, Antonio Russo, Beatrice Taurelli Salimbeni, Giuseppina Sarobba, Francesco Giotta, Ida Paris, Rosa Saltarelli, Daniele Marinelli, Domenico Corsi, Elisabetta Maria Capomolla, Valentina Sini, Luca Moscetti, Lucia Mentuccia, Giuseppe Tonini, Mimma Raffaele, Luca Marchetti, Mauro Minelli, Enzo Maria Ruggeri, Paola Scavina, Olivia Bacciu, Nello Salesi, Lorenzo Livi, Nicola Tinari, Antonino Grassadonia, Angelo Fedele Scinto, Rosalinda Rossi, Maria Rosaria Valerio, Elisabetta Landucci, Simonetta Stani, Beatrice Fratini, Marcello Maugeri-Sacc��, Michele De Tursi, Angela Maione, Daniele Santini, Armando Orlandi, Vito Lorusso, Enrico Cortesi, Giuseppe Sanguineti, Paola Pinnar��, Federico Cappuzzo, Lorenza Landi, Claudio Botti, Federica Tomao, Sonia Cappelli, Giulia Bon, Fabio Pelle, Flavia Cavicchi, Elena Fiorio, Jennifer Foglietta, Simone Scagnoli, Paolo Marchetti, Gennaro Ciliberto and Patrizia Vici in Therapeutic Advances in Medical Oncology

Published
2021
Full Text
View/download PDF

27. Abstract PD11-03: Assessing the impact of 12 months lifestyle interventions on breast cancer secondary prevention: A modeling approach

Author

Pistelli, Mirco, primary, Natalucci, Valentina, additional, Bastianelli, Lucia, additional, Scortichini, Laura, additional, Agostinelli, Veronica, additional, Merloni, Filippo, additional, Savini, Agnese, additional, Capecci, Marianna, additional, Ceravolo, Maria Gabriella, additional, Serrani, Roberta, additional, Ricci, Maurizio, additional, Taus, Marina, additional, Nicolai, Albano, additional, Barbieri, Elena, additional, and Berardi, Rossana, additional

Published
2021
Full Text
View/download PDF

28. Additional file 2 of EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer

Author

Biganzoli, Laura, Cinieri, Saverio, Berardi, Rossana, Pedersini, Rebecca, McCartney, Amelia, Minisini, Alessandro Marco, Caremoli, Elena Rota, Spazzapan, Simon, Magnolfi, Emanuela, Brunello, Antonella, Risi, Emanuela, Palumbo, Raffaella, Leo, Silvana, Colleoni, Marco, Donati, Sara, Placido, Sabino De, Orlando, Laura, Pistelli, Mirco, Parolin, Veronica, Mislang, Anna, Becheri, Dimitri, Puglisi, Fabio, Sanna, Giuseppina, Zafarana, Elena, Boni, Luca, and Mottino, Giuseppe

Abstract

Additional File 2: Supplementary Table 2 (S2). Distribution of CTCAE G2-3 fatigue and neurotoxicity by age and arm of treatment. Reported as N (%) unless otherwise indicated. Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events.

Published
2020
Full Text
View/download PDF

29. Additional file 1 of EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer

Author

Biganzoli, Laura, Cinieri, Saverio, Berardi, Rossana, Pedersini, Rebecca, McCartney, Amelia, Minisini, Alessandro Marco, Caremoli, Elena Rota, Spazzapan, Simon, Magnolfi, Emanuela, Brunello, Antonella, Risi, Emanuela, Palumbo, Raffaella, Leo, Silvana, Colleoni, Marco, Donati, Sara, Placido, Sabino De, Orlando, Laura, Pistelli, Mirco, Parolin, Veronica, Mislang, Anna, Becheri, Dimitri, Puglisi, Fabio, Sanna, Giuseppina, Zafarana, Elena, Boni, Luca, and Mottino, Giuseppe

Abstract

Additional File 1: Supplementary Table 1 (S1). Distribution of AEs by arm in patients aged ≥75 years. Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; /, grade does not exist for this adverse event; ° grade 5 n=1.

Published
2020
Full Text
View/download PDF

30. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence

Author

Krasniqi, E, Pizzuti, L, Barchiesi, G, Sergi, D, Carpano, S, Botti, C, Kayal, R, Sanguineti, G, Marchetti, P, Botticelli, A, Marinelli, D, Gamucci, T, Natoli, C, Grassadonia, A, Tinari, N, Tomao, S, Tonini, G, Santini, D, Michelotti, A, Mentuccia, L, Vaccaro, A, Magnolfi, E, Gelibter, A, Magri, V, Cortesi, E, D'Onofrio, L, Cassano, A, Cazzaniga, M, Moscetti, L, Fabbri, A, Scinto, A, Corsi, D, Carbognin, L, Bria, E, La Verde, N, Garufi, C, Di Stefano, P, Mirabelli, R, Veltri, E, Paris, I, Giotta, F, Lorusso, V, Landucci, E, Ficorella, C, Roselli, M, Adamo, V, Ricciardi, G, Russo, A, Valerio, M, Berardi, R, Pistelli, M, Cannita, K, Zamagni, C, Garrone, O, Baldini, E, Livi, L, Meattini, I, Del Medico, P, Generali, D, De Maria, R, Risi, E, Ciliberto, G, Villa, A, Sperduti, I, Mazzotta, M, Barba, M, Giordano, A, Vici, P, Krasniqi, Eriseld, Pizzuti, Laura, Barchiesi, Giacomo, Sergi, Domenico, Carpano, Silvia, Botti, Claudio, Kayal, Ramy, Sanguineti, Giuseppe, Marchetti, Paolo, Botticelli, Andrea, Marinelli, Daniele, Gamucci, Teresa, Natoli, Clara, Grassadonia, Antonino, Tinari, Nicola, Tomao, Silverio, Tonini, Giuseppe, Santini, Daniele, Michelotti, Aandrea, Mentuccia, Lucia, Vaccaro, Aangela, Magnolfi, Emanuela, Gelibter, Alain, Magri, Valentina, Cortesi, Enrico, D'Onofrio, Loretta, Cassano, Alessandra, Cazzaniga, Marina, Moscetti, Luca, Fabbri, Agnese, Scinto, Angelo Fedele, Corsi, Domenico, Carbognin, Luisa, Bria, Emilio, La Verde, Nicla, Garufi, Carlo, Di Stefano, Pia, Mirabelli, Rossana, Veltri, Enzo, Paris, Ida, Giotta, Francesco, Lorusso, Vito, Landucci, Elisa, Ficorella, Corrado, Roselli, Mario, Adamo, Vincenzo, Ricciardi, Giuseppina, Russo, Antonio, Valerio, Maria Rosaria, Berardi, Rossana, Pistelli, Mirco, Cannita, Katia, Zamagni, Claudio, Garrone, Ornella, Baldini, Editta, Livi, Lorenzo, Meattini, Icro, Del Medico, Pietro, Generali, Daniele, De Maria, Ruggero, Risi, Emanuela, Ciliberto, Gennaro, Villa, Alice, Sperduti, Isabella, Mazzotta, Marco, Barba, Maddalena, Giordano, Antonio, Vici, Patrizia, Krasniqi, E, Pizzuti, L, Barchiesi, G, Sergi, D, Carpano, S, Botti, C, Kayal, R, Sanguineti, G, Marchetti, P, Botticelli, A, Marinelli, D, Gamucci, T, Natoli, C, Grassadonia, A, Tinari, N, Tomao, S, Tonini, G, Santini, D, Michelotti, A, Mentuccia, L, Vaccaro, A, Magnolfi, E, Gelibter, A, Magri, V, Cortesi, E, D'Onofrio, L, Cassano, A, Cazzaniga, M, Moscetti, L, Fabbri, A, Scinto, A, Corsi, D, Carbognin, L, Bria, E, La Verde, N, Garufi, C, Di Stefano, P, Mirabelli, R, Veltri, E, Paris, I, Giotta, F, Lorusso, V, Landucci, E, Ficorella, C, Roselli, M, Adamo, V, Ricciardi, G, Russo, A, Valerio, M, Berardi, R, Pistelli, M, Cannita, K, Zamagni, C, Garrone, O, Baldini, E, Livi, L, Meattini, I, Del Medico, P, Generali, D, De Maria, R, Risi, E, Ciliberto, G, Villa, A, Sperduti, I, Mazzotta, M, Barba, M, Giordano, A, Vici, P, Krasniqi, Eriseld, Pizzuti, Laura, Barchiesi, Giacomo, Sergi, Domenico, Carpano, Silvia, Botti, Claudio, Kayal, Ramy, Sanguineti, Giuseppe, Marchetti, Paolo, Botticelli, Andrea, Marinelli, Daniele, Gamucci, Teresa, Natoli, Clara, Grassadonia, Antonino, Tinari, Nicola, Tomao, Silverio, Tonini, Giuseppe, Santini, Daniele, Michelotti, Aandrea, Mentuccia, Lucia, Vaccaro, Aangela, Magnolfi, Emanuela, Gelibter, Alain, Magri, Valentina, Cortesi, Enrico, D'Onofrio, Loretta, Cassano, Alessandra, Cazzaniga, Marina, Moscetti, Luca, Fabbri, Agnese, Scinto, Angelo Fedele, Corsi, Domenico, Carbognin, Luisa, Bria, Emilio, La Verde, Nicla, Garufi, Carlo, Di Stefano, Pia, Mirabelli, Rossana, Veltri, Enzo, Paris, Ida, Giotta, Francesco, Lorusso, Vito, Landucci, Elisa, Ficorella, Corrado, Roselli, Mario, Adamo, Vincenzo, Ricciardi, Giuseppina, Russo, Antonio, Valerio, Maria Rosaria, Berardi, Rossana, Pistelli, Mirco, Cannita, Katia, Zamagni, Claudio, Garrone, Ornella, Baldini, Editta, Livi, Lorenzo, Meattini, Icro, Del Medico, Pietro, Generali, Daniele, De Maria, Ruggero, Risi, Emanuela, Ciliberto, Gennaro, Villa, Alice, Sperduti, Isabella, Mazzotta, Marco, Barba, Maddalena, Giordano, Antonio, and Vici, Patrizia

Abstract

Body mass index (BMI) is a main indicator of obesity and its association with breast cancer is well established. However, little is known in the metastatic setting, especially in HER2-positive patients. We assessed the influence of BMI on clinical outcomes of patients treated with pertuzumab and/or trastuzumab emtansine (T-DM1) for HER2+ metastatic breast cancer (mBC). BMI was addressed as a categorical variable, being classified on the basis of the following ranges, that is, 18.5–24.9, 25–29.9, and 30.0–34.9, namely, normal weight, overweight, and Class I obesity. The outcomes chosen were progression-free survival to first-line chemotherapy (PFS1) and overall survival (OS). Overall (N = 709), no impact of BMI was observed on PFS1 (p =.15), while BMI ≥ 30 was associated with worse OS (p =.003). In subjects who progressed to first line (N = 575), analyzing data across PFS1 quartiles and strata of disease burden, BMI predicted lower PFS1 in patients within the I PFS1 quartile and with the lowest disease burden (p =.001). Univariate analysis showed a detrimental effect of BMI ≥ 30 on OS for women within the I PFS1 quartile (p =.03). Results were confirmed in multivariate analysis. According to PFS1 quartiles a higher percentage of patients with high BMI and low disease burden progressed within 6 months of therapy. The effect of BMI on prognosis was also confirmed in multivariate analysis of OS for overall population. In our cohort, a BMI ≥ 30 correlated with worse OS in patients with HER2+ mBC who received pertuzumab and/or T-DM1 but had no impact on PFS to first line. BMI predicted worse I PFS1 quartile.

Published
2020

32. PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting

Author

Pizzuti, Laura, primary, Krasniqi, Eriseld, additional, Sperduti, Isabella, additional, Barba, Maddalena, additional, Gamucci, Teresa, additional, Mauri, Maria, additional, Veltri, Enzo Maria, additional, Meattini, Icro, additional, Berardi, Rossana, additional, Di Lisa, Francesca Sofia, additional, Natoli, Clara, additional, Pistelli, Mirco, additional, Iezzi, Laura, additional, Risi, Emanuela, additional, D’Ostilio, Nicola, additional, Tomao, Silverio, additional, Ficorella, Corrado, additional, Cannita, Katia, additional, Riccardi, Ferdinando, additional, Cassano, Alessandra, additional, Bria, Emilio, additional, Fabbri, Maria Agnese, additional, Mazzotta, Marco, additional, Barchiesi, Giacomo, additional, Botticelli, Andrea, additional, D’Auria, Giuliana, additional, Ceribelli, Anna, additional, Michelotti, Andrea, additional, Russo, Antonio, additional, Salimbeni, Beatrice Taurelli, additional, Sarobba, Giuseppina, additional, Giotta, Francesco, additional, Paris, Ida, additional, Saltarelli, Rosa, additional, Marinelli, Daniele, additional, Corsi, Domenico, additional, Capomolla, Elisabetta Maria, additional, Sini, Valentina, additional, Moscetti, Luca, additional, Mentuccia, Lucia, additional, Tonini, Giuseppe, additional, Raffaele, Mimma, additional, Marchetti, Luca, additional, Minelli, Mauro, additional, Ruggeri, Enzo Maria, additional, Scavina, Paola, additional, Bacciu, Olivia, additional, Salesi, Nello, additional, Livi, Lorenzo, additional, Tinari, Nicola, additional, Grassadonia, Antonino, additional, Fedele Scinto, Angelo, additional, Rossi, Rosalinda, additional, Valerio, Maria Rosaria, additional, Landucci, Elisabetta, additional, Stani, Simonetta, additional, Fratini, Beatrice, additional, Maugeri-Saccà, Marcello, additional, De Tursi, Michele, additional, Maione, Angela, additional, Santini, Daniele, additional, Orlandi, Armando, additional, Lorusso, Vito, additional, Cortesi, Enrico, additional, Sanguineti, Giuseppe, additional, Pinnarò, Paola, additional, Cappuzzo, Federico, additional, Landi, Lorenza, additional, Botti, Claudio, additional, Tomao, Federica, additional, Cappelli, Sonia, additional, Bon, Giulia, additional, Pelle, Fabio, additional, Cavicchi, Flavia, additional, Fiorio, Elena, additional, Foglietta, Jennifer, additional, Scagnoli, Simone, additional, Marchetti, Paolo, additional, Ciliberto, Gennaro, additional, and Vici, Patrizia, additional

Published
2021
Full Text
View/download PDF

34. Prospective observational study of taste assay in patients with solid tumors treated with standard chemotherapy (POTATO)

Author

Giampieri, Riccardo, primary, Pelati, Elisa, additional, Mobili, Aurora Anna, additional, Copparoni, Cecilia, additional, Crocetti, Sonia, additional, Baleani, Maria Giuditta, additional, Pistelli, Mirco, additional, Pugnaloni, Sofia, additional, Alia, Sonila, additional, Mariani, Carlotta, additional, Vignini, Arianna, additional, Taus, Marina, additional, and Berardi, Rossana, additional

Published
2020
Full Text
View/download PDF

35. EFFECT: A randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer

Author

Biganzoli, Laura, primary, Cinieri, Saverio, additional, Berardi, Rossana, additional, Pedersini, Rebecca, additional, McCartney, Amelia, additional, Minisini, Alessandro Marco, additional, Caremoli, Elena Rota, additional, Spazzapan, Simon, additional, Magnolfi, Emanuela, additional, Brunello, Antonella, additional, Risi, Emanuela, additional, Palumbo, Raffaella, additional, Leo, Silvana, additional, Colleoni, Marco, additional, Donati, Sara, additional, De Placido, Sabino, additional, Orlando, Laura, additional, Pistelli, Mirco, additional, Parolin, Veronica, additional, Mislang, Anna, additional, Becheri, Dimitri, additional, Puglisi, Fabio, additional, Sanna, Giuseppina, additional, Zafarana, Elena, additional, Boni, Luca, additional, and Mottino, Giuseppe, additional

Published
2020
Full Text
View/download PDF

36. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real‐world evidence

Author

Krasniqi, Eriseld, primary, Pizzuti, Laura, additional, Barchiesi, Giacomo, additional, Sergi, Domenico, additional, Carpano, Silvia, additional, Botti, Claudio, additional, Kayal, Ramy, additional, Sanguineti, Giuseppe, additional, Marchetti, Paolo, additional, Botticelli, Andrea, additional, Marinelli, Daniele, additional, Gamucci, Teresa, additional, Natoli, Clara, additional, Grassadonia, Antonino, additional, Tinari, Nicola, additional, Tomao, Silverio, additional, Tonini, Giuseppe, additional, Santini, Daniele, additional, Michelotti, Aandrea, additional, Mentuccia, Lucia, additional, Vaccaro, Aangela, additional, Magnolfi, Emanuela, additional, Gelibter, Alain, additional, Magri, Valentina, additional, Cortesi, Enrico, additional, D’Onofrio, Loretta, additional, Cassano, Alessandra, additional, Cazzaniga, Marina, additional, Moscetti, Luca, additional, Fabbri, Agnese, additional, Scinto, Angelo Fedele, additional, Corsi, Domenico, additional, Carbognin, Luisa, additional, Bria, Emilio, additional, La Verde, Nicla, additional, Garufi, Carlo, additional, Di Stefano, Pia, additional, Mirabelli, Rossana, additional, Veltri, Enzo, additional, Paris, Ida, additional, Giotta, Francesco, additional, Lorusso, Vito, additional, Landucci, Elisa, additional, Ficorella, Corrado, additional, Roselli, Mario, additional, Adamo, Vincenzo, additional, Ricciardi, Giuseppina, additional, Russo, Antonio, additional, Valerio, Maria Rosaria, additional, Berardi, Rossana, additional, Pistelli, Mirco, additional, Cannita, Katia, additional, Zamagni, Claudio, additional, Garrone, Ornella, additional, Baldini, Editta, additional, Livi, Lorenzo, additional, Meattini, Icro, additional, Del Medico, Pietro, additional, Generali, Daniele, additional, De Maria, Ruggero, additional, Risi, Emanuela, additional, Ciliberto, Gennaro, additional, Villa, Alice, additional, Sperduti, Isabella, additional, Mazzotta, Marco, additional, Barba, Maddalena, additional, Giordano, Antonio, additional, and Vici, Patrizia, additional

Published
2020
Full Text
View/download PDF

37. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience

Author

Pizzuti, Laura, Giordano, Antonio, Michelotti, Andrea, Mazzotta, Marco, Natoli, Clara, Gamucci, Teresa, De Angelis, Claudia, Landucci, Elisabetta, Diodati, Lucrezia, Iezzi, Laura, Mentuccia, Lucia, Fabbri, Agnese, Barba, Maddalena, Sanguineti, Giuseppe, Marchetti, Paolo, Tomao, Silverio, Mariani, Luciano, Paris, Ida, Lorusso, Vito, Vallarelli, Simona, Cassano, Alessandra, Airoldi, Francesca, Orlandi, Armando, Moscetti, Luca, Sergi, Domenico, Sarobba, Maria Giuseppina, Tonini, Giuseppe, Santini, Daniele, Sini, Valentina, Veltri, Enzo, Vaccaro, Angela, Ferrari, Laura, De Tursi, Michele, Tinari, Nicola, Grassadonia, Antonino, Greco, Filippo, Botticelli, Andrea, La Verde, Nicla, Zamagni, Claudio, Rubino, Daniela, Cortesi, Enrico, Magri, Valentina, Pomati, Giulia, Scagnoli, Simone, Capomolla, Elisabetta, Kayal, Ramy, Scinto, Angelo Fedele, Corsi, Domenico Cristiano, Cazzaniga, Marina, Laudadio, Lucio, Forciniti, Samantha, Mancini, Maria, Carbognin, Luisa, Seminara, Patrizia, Barni, Sandro, Samaritani, Riccardo, Roselli, Mario, Portarena, Ilaria, Dello Russo, Antonio, Ficorella, Corrado, Cannita, Katia, Carpano, Silvia, Pistelli, Mirco, Berardi, Rossana, De Maria Marchiano, Ruggero, Sperduti, Isabella, Ciliberto, Gennaro, Vici, Patrizia, Cassano, Alessandra (ORCID:0000-0002-3311-7163), Orlandi, Armando (ORCID:0000-0001-5253-4678), Corsi, Domenico, De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583), Pizzuti, Laura, Giordano, Antonio, Michelotti, Andrea, Mazzotta, Marco, Natoli, Clara, Gamucci, Teresa, De Angelis, Claudia, Landucci, Elisabetta, Diodati, Lucrezia, Iezzi, Laura, Mentuccia, Lucia, Fabbri, Agnese, Barba, Maddalena, Sanguineti, Giuseppe, Marchetti, Paolo, Tomao, Silverio, Mariani, Luciano, Paris, Ida, Lorusso, Vito, Vallarelli, Simona, Cassano, Alessandra, Airoldi, Francesca, Orlandi, Armando, Moscetti, Luca, Sergi, Domenico, Sarobba, Maria Giuseppina, Tonini, Giuseppe, Santini, Daniele, Sini, Valentina, Veltri, Enzo, Vaccaro, Angela, Ferrari, Laura, De Tursi, Michele, Tinari, Nicola, Grassadonia, Antonino, Greco, Filippo, Botticelli, Andrea, La Verde, Nicla, Zamagni, Claudio, Rubino, Daniela, Cortesi, Enrico, Magri, Valentina, Pomati, Giulia, Scagnoli, Simone, Capomolla, Elisabetta, Kayal, Ramy, Scinto, Angelo Fedele, Corsi, Domenico Cristiano, Cazzaniga, Marina, Laudadio, Lucio, Forciniti, Samantha, Mancini, Maria, Carbognin, Luisa, Seminara, Patrizia, Barni, Sandro, Samaritani, Riccardo, Roselli, Mario, Portarena, Ilaria, Dello Russo, Antonio, Ficorella, Corrado, Cannita, Katia, Carpano, Silvia, Pistelli, Mirco, Berardi, Rossana, De Maria Marchiano, Ruggero, Sperduti, Isabella, Ciliberto, Gennaro, Vici, Patrizia, Cassano, Alessandra (ORCID:0000-0002-3311-7163), Orlandi, Armando (ORCID:0000-0001-5253-4678), Corsi, Domenico, and De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583)

Abstract

Data from 423 human epidermal growth factor receptor 2-negative (HER2−), hormone receptor-positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian cancer centers and analyzed for treatment outcomes. Overall, 158 patients were treated in first line and 265 in second/later lines. We observed 19 complete responses and 112 partial responses. The overall response rate (ORR) was 31% (95% confidence interval [CI], 26.6–35.4) and clinical benefit was 52.7% (95% CI, 48–57.5). ORR was negatively affected by prior exposure to everolimus/exemestane (p = 0.002) and favorably influenced by early line-treatment (p < 0.0001). At 6 months, median progression-free survival was 12 months (95% CI, 8–16) and median overall survival was 24 months (95% CI, 17–30). More favorable outcomes were associated with palbociclib in early lines, no visceral metastases and no prior everolimus/exemestane. The main toxicity reported was neutropenia. Our results provide further support to the use of palbociclib with ET in HER2−, HR+ aBC. Differences in outcomes across patients subsets remain largely unexplained.

Published
2019

38. Correction: Everolimus (Eve) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9:77 (34639-34640) DOI: 10.18632/oncotarget.25874)

Author

Cazzaniga, Marina, Verusio, Claudio, Ciccarese, Mariangela, Fumagalli, Alberto, Sartori, Donata, Ancona, Chiara, Airoldi, Mario, Moretti, Gabriella, Ficorella, Corrado, Arcangeli, Valentina, Diodati, Lucrezia, Zambelli, Alberto, Febbraro, Antonio, Generali, Daniele, Pistelli, Mirco, Garrone, Ornella, Musolino, Antonino, Vici, Patrizia, Maur, Michela, Mentuccia, Lucia, La Verde, Nicla, Bianchi, Giulia, Artale, Salvatore, Blasi, Livio, Piezzo, Michela, Atzori, Francesco, Turletti, Anna, Benedetto, Chiara, Cursano, Maria Concetta, Fabi, Alessandra, Gebbia, Vittorio, Schirone, Antonio, Palumbo, Raffaella, Ferzi, Antonella, Frassoldati, Antonio, Scavelli, Claudio, and Clivio, Luca

Subjects
Oncology
Published
2018

39. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti‐HER2 agents in the real world setting

Author

Pizzuti, Laura, primary, Krasniqi, Eriseld, additional, Barchiesi, Giacomo, additional, Della Giulia, Marina, additional, Izzo, Fiorentino, additional, Sanguineti, Giuseppe, additional, Marchetti, Paolo, additional, Mazzotta, Marco, additional, Giusti, Raffaele, additional, Botticelli, Andrea, additional, Gamucci, Teresa, additional, Natoli, Clara, additional, Grassadonia, Antonino, additional, Tinari, Nicola, additional, Iezzi, Laura, additional, Tomao, Silverio, additional, Tomao, Federica, additional, Tonini, Giuseppe, additional, Santini, Daniele, additional, Astone, Antonio, additional, Michelotti, Andrea, additional, De Angelis, Claudia, additional, Mentuccia, Lucia, additional, Vaccaro, Angela, additional, Magnolfi, Emanuela, additional, Gelibter, Alain, additional, Magri, Valentina, additional, Cortesi, Enrico, additional, D'Onofrio, Loretta, additional, Cassano, Alessandra, additional, Rossi, Ernesto, additional, Cazzaniga, Marina, additional, Moscetti, Luca, additional, Omarini, Claudia, additional, Piacentini, Federico, additional, Fabbri, Maria A., additional, Scinto, Angelo F., additional, Corsi, Domenico, additional, Carbognin, Luisa, additional, Bria, Emilio, additional, La Verde, Nicla, additional, Samaritani, Riccardo, additional, Garufi, Carlo, additional, Barni, Sandro, additional, Mirabelli, Rosanna, additional, Sarmiento, Roberta, additional, Veltri, Enzo M., additional, D'Auria, Giuliana, additional, Paris, Ida, additional, Giotta, Francesco, additional, Lorusso, Vito, additional, Cardillo, Franca, additional, Landucci, Elisabetta, additional, Mauri, Maria, additional, Ficorella, Corrado, additional, Roselli, Mario, additional, Adamo, Vincenzo, additional, Ricciardi, Giuseppina R.R., additional, Russo, Antonio, additional, Berardi, Rossana, additional, Pistelli, Mirco, additional, Fiorio, Elena, additional, Cannita, Katia, additional, Sini, Valentina, additional, D'Ostilio, Nicola, additional, Foglietta, Jennifer, additional, Greco, Filippo, additional, Zamagni, Claudio, additional, Garrone, Ornella, additional, Di Cocco, Barbara, additional, Baldini, Editta, additional, Livi, Lorenzo, additional, Desideri, Isacco, additional, Meattini, Icro, additional, Sarobba, Giuseppina, additional, Del Medico, Pietro, additional, De Tursi, Michele, additional, Generali, Daniele, additional, De Maria, Ruggero, additional, Risi, Emanuela, additional, Ciliberto, Gennaro, additional, Sperduti, Isabella, additional, Villa, Alice, additional, Barba, Maddalena, additional, Di Leo, Angelo, additional, and Vici, Patrizia, additional

Published
2019
Full Text
View/download PDF

40. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor‐positive, advanced breast cancer: A real‐world experience

Author

Pizzuti, Laura, primary, Giordano, Antonio, additional, Michelotti, Andrea, additional, Mazzotta, Marco, additional, Natoli, Clara, additional, Gamucci, Teresa, additional, De Angelis, Claudia, additional, Landucci, Elisabetta, additional, Diodati, Lucrezia, additional, Iezzi, Laura, additional, Mentuccia, Lucia, additional, Fabbri, Agnese, additional, Barba, Maddalena, additional, Sanguineti, Giuseppe, additional, Marchetti, Paolo, additional, Tomao, Silverio, additional, Mariani, Luciano, additional, Paris, Ida, additional, Lorusso, Vito, additional, Vallarelli, Simona, additional, Cassano, Alessandra, additional, Aroldi, Francesca, additional, Orlandi, Armando, additional, Moscetti, Luca, additional, Sergi, Domenico, additional, Sarobba, Maria Giuseppina, additional, Tonini, Giuseppe, additional, Santini, Daniele, additional, Sini, Valentina, additional, Veltri, Enzo, additional, Vaccaro, Angela, additional, Ferrari, Laura, additional, De Tursi, Michele, additional, Tinari, Nicola, additional, Grassadonia, Antonino, additional, Greco, Filippo, additional, Botticelli, Andrea, additional, La Verde, Nicla, additional, Zamagni, Claudio, additional, Rubino, Daniela, additional, Cortesi, Enrico, additional, Magri, Valentina, additional, Pomati, Giulia, additional, Scagnoli, Simone, additional, Capomolla, Elisabetta, additional, Kayal, Ramy, additional, Scinto, Angelo Fedele, additional, Corsi, Domenico, additional, Cazzaniga, Marina, additional, Laudadio, Lucio, additional, Forciniti, Samantha, additional, Mancini, Maria, additional, Carbognin, Luisa, additional, Seminara, Patrizia, additional, Barni, Sandro, additional, Samaritani, Riccardo, additional, Roselli, Mario, additional, Portarena, Ilaria, additional, Russo, Antonio, additional, Ficorella, Corrado, additional, Cannita, Katia, additional, Carpano, Silvia, additional, Pistelli, Mirco, additional, Berardi, Rossana, additional, De Maria, Ruggero, additional, Sperduti, Isabella, additional, Ciliberto, Gennaro, additional, and Vici, Patrizia, additional

Published
2018
Full Text
View/download PDF

41. Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

Author

Cazzaniga, Marina, Verusio, Claudio, Ciccarese, Mariangela, Fumagalli, Alberto, Sartori, Donata, Valerio, Maria Rosaria, Airoldi, Mario, Moretti, Gabriella, Ficorella, Corrado, Arcangeli, Valentina, Diodati, Lucrezia, Zambelli, Alberto, Febbraro, Antonio, Generali, Daniele, Pistelli, Mirco, Garrone, Ornella, Musolino, Antonino, Vici, Patrizia, Maur, Michela, Mentuccia, Lucia, La Verde, Nicla, Bianchi, Giulia, Artale, Salvatore, Blasi, Livio, Piezzo, Michela, Atzori, Francesco, Turletti, Anna, Benedetto, Chiara, Cursano, Maria Concetta, Fabi, Alessandra, Gebbia, Vittorio, Schirone, Alessio, Palumbo, Raffaella, Ferzi, Antonella, Frassoldati, Antonio, Scavelli, Claudio, Clivio, Luca, and Torri, Valter

Subjects
Oncology, Correction
Abstract

The present analysis focuses on real-world data of Everolimus-Exemestane in advanced HR+ve, HER2-ve elderly breast cancer patients (aged 65 years) included in the EVA study, with unique findings in those aged 70 years.Data are collected from clinical records and analysed according to age cut-off (65 years; 65 - 69 years and {greater than or equal to} 70 years). Relationship of analyzed variables with response were tested by mean of a Mantel-Haenszel chi square test. Time to event analysis was described by Kaplan Meier approach and association with baseline characteristics was analysed by stratified log-rank test and proportional hazard model.From July 2013 to December 2015, the EVA study enrolled overall 404 pts. 154 patients out of 404 (38,1%) were aged {greater than or equal to} 65 years, of whom 87 were {greater than or equal to} 70 years. Median duration of EVE treatment was 28.5 weeks (95% CI 19.0 - 33.8) in patients aged 65-69 years and 24,4 weeks (95% CI 19,2 - 33,2) in those aged {greater than or equal to} 70 years. Fewer patients aged 65 years received the highest EVE Dose-Intensity (7.5 mg/day) in comparison to younger patients (49,6% vs. 66,8%). Grade 3-4 toxicities occurred to 55 patients (35,7%), mainly stomatitis (10,9%), rash (5,8%) and non-infectious pneumonitis (NIP) (3,6%). Some toxicities, such as weight loss and anaemia were peculiarly observed in patients aged {greater than or equal to} 70 years. Five treatment-related deaths were collected (3,2%).EVE-EXE combination remains one of the potential treatments in HR+ patients also for elderly ones.

Published
2018

42. Is There Still a Role for Endocrine Therapy Alone in HR+/HER2– Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies

Author

Cazzaniga, Marina Elena, Verusio, Claudio, Ciccarese, Mariangela, Fumagalli, Alberto, Sartori, Donata, Valerio, Maria Rosaria, Airoldi, Mario, Moretti, Gabriella, Ficorella, Corrado, Gianni, Lorenzo, Michelotti, Andrea, Zambelli, Alberto, Febbraro, Antonio, Generali, Daniele, Pistelli, Mirco, Garrone, Ornella, Musolino, Antonino, Vici, Patrizia, Maur, Michela, and Mentuccia, Lucia

Subjects
ANTINEOPLASTIC agents, BREAST tumors, CANCER patients, DOSE-response relationship in biochemistry, METASTASIS, TREATMENT effectiveness, TREATMENT duration, DESCRIPTIVE statistics
Abstract

Background: Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated with HD-FUL as first-line treatment in terms of median duration of treatment and the overall response rate in a real-world setting. Methods: For the purpose of the present analysis, we considered two data sets of HR+ ABC patients collected in Italy between 2012 and 2015 (EVA and GIM-13 AMBRA studies). Results: Eighty-one and 91 patients have been identified from the two data sets. The median age was 63 years (range 35–82) for the EVA and 57.8 years (range 35.0–82.3) for the AMBRA patients. ORRs were 23.5 and 24.3% in the whole population, 26.9% in the patients with bone only, and 21.8 and 21.4% in those with visceral metastases. The median duration of HD-FUL was 11.6 months (range 1–48) and 12.4 months (range 2.9–70.0) in the two data sets, respectively. Conclusion: These data suggest that HD-FUL should still continue to play a significant role as first-line therapy in HR+ ABC patients. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

43. Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

Author

Cazzaniga, Marina, primary, Verusio, Claudio, additional, Ciccarese, Mariangela, additional, Fumagalli, Alberto, additional, Sartori, Donata, additional, Valerio, Maria Rosaria, additional, Airoldi, Mario, additional, Moretti, Gabriella, additional, Ficorella, Corrado, additional, Arcangeli, Valentina, additional, Diodati, Lucrezia, additional, Zambelli, Alberto, additional, Febbraro, Antonio, additional, Generali, Daniele, additional, Pistelli, Mirco, additional, Garrone, Ornella, additional, Musolino, Antonino, additional, Vici, Patrizia, additional, Maur, Michela, additional, Mentuccia, Lucia, additional, La Verde, Nicla, additional, Bianchi, Giulia, additional, Artale, Salvatore, additional, Blasi, Livio, additional, Piezzo, Matilde, additional, Atzori, Francesco, additional, Turletti, Anna, additional, Benedetto, Chiara, additional, Cursano, Maria Concetta, additional, Fabi, Alessandra, additional, Gebbia, Vittorio, additional, Schirone, Alessio, additional, Palumbo, Raffaella, additional, Ferzi, Antonella, additional, Frassoldati, Antonio, additional, Scavelli, Claudio, additional, Clivio, Luca, additional, and Torri on behalf of The EVA Study Group, Valter, additional

Published
2018
Full Text
View/download PDF

47. Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy

Author

Berardi, Rossana, primary, Santoni, Matteo, additional, Newsom-Davis, Thomas, additional, Caramanti, Miriam, additional, Rinaldi, Silvia, additional, Tiberi, Michela, additional, Morgese, Francesca, additional, Torniai, Mariangela, additional, Pistelli, Mirco, additional, Onofri, Azzurra, additional, Bower, Marc, additional, and Cascinu, Stefano, additional

Published
2016
Full Text
View/download PDF

48. Paclitaxel and Bevacizumab in First Line-Treatment Patients with HER-2 Negative Advanced Breast Cancer: Who could Benefit?

Author

Pistelli, Mirco, Ballatore, Zelmira, De Lisa Mariagrazia, Caramanti, Miriam, Pagliacci, Alessandra, Battelli, Nicola, Ridolfi, Francesca, Santinelli, Alfredo, Biscotti, Tommasina, Berardi, Rossana, and Cascinu, Stefano

Subjects
Oncology, medicine.medical_specialty, Univariate analysis, Taxane, Bevacizumab, business.industry, Cancer, General Medicine, medicine.disease, Metastatic breast cancer, Surgery, chemistry.chemical_compound, Regimen, Breast cancer, Paclitaxel, chemistry, Internal medicine, medicine, business, medicine.drug
Abstract

Background: Angiogenesis is essential for tumor growth and development of metastases in human breast cancer. Randomized studies have shown that bevacizumab (inhibitor of VEGF) combined with taxane-based regimens increases response rates and prolongs Progression-Free Survival (PFS) of patients with Metastatic Breast Cancer (MBC). However predictive or prognostic markers that identify the appropriate target population, thus improving the cost-effectiveness ratio of this treatment, are still needed. In this retrospective analysis, we investigated the impact of traditional clinical and pathological features in order to identify the subgroups of patients who derive the greatest benefit from antiangiogenic-agents. Patients and methods: Retrospectively, we included consecutive patients treated with bevacizumab (10 mg/Kg on days 1 and 15) and paclitaxel (90 mg/m2, on days 1, 8 and 15) as first-line treatment for HER2-negative MBC at our Institution between June 2007 and December 2012. Results: 33 patients were included. Median age was 50 years (31-68). 78. 8%, 12.1% and 9.1% of patients had luminal B, triple negative and luminal A breast cancer, respectively. 66. 6% of patients had visceral disease. The overall response rate was 31.2%. Median PFS and overall survival (OS) were 7.7 months (range 1. 9-14.0 months) and 95.2 months (range 11.6-205.8 months), respectively. Univariate analysis highlighted a statistically significant relationship between PFS to the first line and the following factors: relapse-free survival (RFS 12 months; p

Published
2014

49. Eribulin in Male Patients With Breast Cancer: The First Report of Clinical Outcomes

Author

Giotta, Francesco, primary, Acito, Luigi, additional, Candeloro, Giampiero, additional, Del Medico, Pietro, additional, Gadaleta‐Caldarola, Gennaro, additional, Giordano, Guido, additional, Gueli, Rossana, additional, Lugini, Antonio, additional, Magri, Valentina, additional, Mandarà, Marta, additional, Masci, Giovanna, additional, Pisconti, Salvatore, additional, Pistelli, Mirco, additional, Rizzi, Anna, additional, Salesi, Nello, additional, Schirone, Alessio, additional, Scognamiglio, Giovanni, additional, Tedeschi, Maria, additional, and Zucchinelli, Patrizia, additional

Published
2016
Full Text
View/download PDF

50. Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials

Author

Berardi, Rossana, primary, Santoni, Matteo, additional, Rinaldi, Silvia, additional, Nunzi, Emilia, additional, Smerilli, Alessia, additional, Caramanti, Miriam, additional, Morgese, Francesca, additional, Torniai, Mariangela, additional, Savini, Agnese, additional, Fiordoliva, Ilaria, additional, Onofri, Azzurra, additional, Pistelli, Mirco, additional, Taccaliti, Augusto, additional, and Cascinu, Stefano, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results